FASTIN

LOE Approaching

phentermine hydrochloride

NDAORALCAPSULE
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

obesity, amphetamine (d- and d l l-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system…

Indications (1)

Clinical Trials (5)

NCT07299084Phase 1Recruiting

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

Started Jan 2026
40 enrolled
Diabetes Mellitus, Type 2OverweightObesity
NCT07313813Phase 1Recruiting

A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

Started Dec 2025
20 enrolled
Type 2 Diabetes Mellitus (T2DM)
NCT07225816Phase 1Recruiting

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Started Nov 2025
75 enrolled
Obesity
NCT06487416Phase 1Active Not Recruiting

A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions

Started Jun 2024
NCT06326671Phase 1Active Not Recruiting

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Started Feb 2024